LAB · XBRL financial data

Standard Biotools financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LAB's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q3 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	28*	46	37	45	47*	41	22	20	24*	21	20	19
Cost of goods and services sold	15*	21	22	22	25*	21	11	10	12*	10	10	9
Gross profit	13*	24	15	23	22*	20	11	9	11*	11	11	11
Research and development	7*	16	19	13	14*	11	6	6	8*	2	2	2
Selling, general and administrative	21*	47	38	34	38*	39	28	27	25*	19	16	17
Total operating expenses	35*	84	65	55	55*	53	36	42	36*	24	36	31
Operating income (loss)	(21)*	(60)	(51)	(32)	(33)*	(33)	(26)	(33)	(25)*	(12)	(25)	(20)
Interest expense	1*	—	—	—	—	—	—	—	—	—	—	—
Other income (expense)	3*	(2)	0	1	(4)*	4	5	(2)	1*	(6)	(1)	(0)
Income tax expense (benefit)	(0)*	0	0	0	0*	(0)	(1)	(1)	(36)*	0	0	0
Net income (loss)	(20)*	(32)	(46)	(27)	(34)*	(26)	(33)	(35)	19*	127	(27)	13
Earnings per share, basic USD per share	(0.25)*	(0.27)	(0.12)	(0.07)	(0.09)*	(0.07)	(0.09)	(0.09)	0.05*	0.33	(0.07)	0.03
Earnings per share, diluted USD per share	(0.25)*	(0.27)	(0.12)	(0.07)	(0.09)*	(0.07)	(0.09)	(0.09)	0.05*	0.33	(0.07)	0.03
Weighted average shares, basic millions of shares	80*	294	372	372	375*	378	380	383	385*	388	391	394
Weighted average shares, diluted millions of shares	80*	294	372	372	375*	378	380	383	385*	388	391	394

Fiscal quarters (LAB's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q3 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	52	287	270	211	167	151	159	129	121	266	270	267
Marketable securities	63	175	125	156	126	107	78	65	67	189	207	194
Accounts receivable	20	36	32	35	34	35	15	14	13	17	16	13
Inventory	21	40	43	43	41	42	24	25	20	19	17	18
Prepaid and other current assets	3	9	10	9	9	8	7	8	5	6	7	6
Total current assets	158	548	480	454	376	344	506	472	454	521	517	497
Property and equipment, net	24	45	43	42	43	44	23	21	19	17	15	13
Right-of-use asset	31	33	32	30	29	27	25	23	27	26	24	23
Goodwill	106	106	106	106	111	112	—	—	—	—	—	—
Total assets	323	778	709	682	612	580	557	540	568	639	627	635
Accounts payable	9	13	13	11	12	12	7	7	5	8	10	3
Accrued liabilities	9	30	32	32	31	22	24	31	30	16	30	30
Total current liabilities	109	122	124	121	66	56	98	108	108	42	57	51
Lease liability, non-current	30	31	30	28	26	25	23	22	25	24	22	21
Total liabilities	160	200	198	192	141	125	132	140	143	78	87	80
Accumulated deficit	(1,001)	(1,079)	(1,125)	(1,152)	(1,186)	(1,212)	(1,245)	(1,280)	(1,261)	(1,133)	(1,160)	(1,147)
Total stockholders' equity	(148)	577	510	489	472	455	425	400	424	561	540	556
Total liabilities and equity	323	778	709	682	612	580	557	540	568	639	627	635
Common shares outstanding (cover page) millions of shares	290	372	371	372	379	380	382	385	390	390	393	395

Fiscal quarters (LAB's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q3 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(20)*	(32)	(46)	(27)	(34)*	(26)	(33)	(35)	19*	127	(27)	13
Stock-based compensation	3*	12	7*	6*	7*	9	6*	8*	6*	9	4*	4*
Depreciation and amortization	1*	5	4	4	—	—	—	—	—	—	—	—
Net cash from operating activities	(14)*	(62)	(39)*	(28)*	(14)*	(30)	(21)*	(22)*	(1)*	(47)	(10)*	(6)*
Purchases of property and equipment	0*	1	2*	2*	3*	5	2*	1*	0*	1	0*	0*
Net cash from investing activities	(13)*	318	50*	(31)*	26*	15	28*	(7)*	(8)*	191	14*	5*
Share repurchases	0*	11	29*	0*	0*	0	0*	0*	0*	—	—	—
Net cash from financing activities	(1)*	(20)	(28)*	(0)*	(55)*	(0)	0*	(0)*	1*	(0)	(0)*	(1)*
Net change in cash	(28)*	236	(17)*	(59)*	(43)*	(15)	8*	(29)*	(9)*	145	4*	(3)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Standard Biotools	270	20	(10)*	392.6M	46.2 quarters	Q2 FY26 10-QJun 30, 2026
Aquestive Therapeutics	90	7.6	(7)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Siga Technologies	118	41	15*	71.8M	—	Q2 FY26 10-QJun 30, 2026
Ocugen	100	1.5	(12)*	339.1M	8.2 quarters	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56	11	(17)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176	14	(42)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	62	70	(28)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Nektar Therapeutics	39	10	(76)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	68	not reported	(33)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.